Abstract
Introduction Acute respiratory distress syndrome (ARDS) is a severe inflammatory process of the lung, often due to sepsis, and poses significant mortality burden in intensive care units. Here we conducted the largest genome-wide association study (GWAS) of sepsis-associated ARDS to identify novel genetic risk loci that can help guide the development of new therapeutic options.
Methods We performed a case-control GWAS in 716 patients with sepsis-associated ARDS and 4,399 at-risk sepsis controls from three independent studies. Results were meta-analysed across the three studies, with significance set at p<5×10-8. Suggestive associations were declared for variants exhibiting consistent effects, likely to replicate and nominal significance (p<0.05) in all three studies. Prioritised loci were subjected to Bayesian fine mapping, in-silico functional assessments, and gene-based rare variant collapsing analysis using whole exome sequencing (WES) data. Two independent studies with 430 ARDS cases and 1,398 controls served as replication samples.
Results We identified a variant showing genome-wide significant association with sepsis-associated ARDS risk intergenic to ANKRD31 and HMGCR, previously linked to cholesterol metabolism. Suggestive associations were found for eight other variants. The rare exonic variant analysis showed associations between HMGCR and POC5 and sepsis-associated ARDS at nominal level (p<0.05). While no nominal significance was achieved in the two additional validation cohorts, three variants exhibited a consistent direction of effects across all 5 studies.
Conclusion A common variant intergenic to ANKRD31 and HMGCR was associated with sepsis-associated ARDS risk, suggesting a link between cholesterol metabolism and ARDS risk. Validation in independent studies is needed.
Competing Interest Statement
DC and BLY are full-time employees of Genentech. BLY holds stock options in Roche. MS receives funding from Pfizer for a project not related to this research. LVW reports research funding from GlaxoSmithKline, Genentech and Orion Pharma, and consultancy for Galapagos and GlaxoSmithKline, outside of the submitted work. The other authors declare no competing interests.
Funding Statement
BGG is supported by Wellcome Trust (grant 221680/Z/20/Z). For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. ESP and ETH are funded by Gobierno de Canarias and Social European Fund ′Canarias Avanza con Europa′ (grants TESIS2022010042 and TESIS2021010046 respectively) and Social European Fund Plus (EST2023010007). VEK is funded by National Heart, Lung, and Blood Institute (grant K01HL157755) and ATS Research Program. AS was supported by the German Ministry of Education and Research (01 ZZ 1803C) within the Smart Medical Information Technology for Healthcare consortium. LVW holds a GlaxoSmithKline Asthma + Lung UK Chair in Respiratory Research (C17-1). JV was funded by Instituto de Salud Carlos III, Madrid, Spain (PI19/00141, AC21_2/00039), ERAPerMed (JTC_2021), the European Regional Development Funds, Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias. CF is funded by Instituto de Salud Carlos III (PI1400844, PI17/00610, PI20/00876 and PI23/00980); European Union (ERDF) ′A way of making Europe′, Agencia Estatal de Investigacion (RTC-2017-6471-1), ITER agreements (OA17/008 and OA23/043), and Cabildo Insular de Tenerife (CGIEU0000219140 and ′Apuestas cientificas del ITER para colaborar en la lucha contra la COVID-19′). The SepNet GWAS project was supported by the Paul-Martini-Sepsis Research Group (funded by the Thuringian Ministry of Education, Science, and Culture [ProExcellence; grant PE 108-2]), the Thuringian Foundation for Technology, Innovation, and Research, the German Sepsis Society, and the Jena Center of Sepsis Control and Care (funded by the German Ministry of Education and Research [01 EO 1002 and 01 EO 1502]). The VISEP and MAXSEP trials from the SepNet Study Group were supported by a German Ministry of Education and Research grant (01 KI 0106), and by unrestricted grants from B Braun, HemoCue, Novo Nordisk, AstraZeneca (Wedel, Germany), and Bayer HealthCare (Leverkusen, Germany). This research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. This research includes use of the UK Biobank through application 648 and used the ALICE High Performance Computing Facility at the University of Leicester.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The GEN-SEP study was approved by the Ethics Committee from the Hospital Universitario de Canarias (CHUNSC_2018-16). Genetic analyses of SepNet (with separate patient consent for genetic analyses) were integrated in the randomized clinical trials VISEP (recruitment in 2003-2005, registration number: NCT00135473) and MAXSEP (recruitment in 2007-2010, registration number: NCT00534287). All these participating studies were performed according to The Code of Ethics of the World Medical Association (Declaration of Helsinki), and informed consent was obtained from all subjects or their representatives. UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos